ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its quarterly earnings data on Wednesday. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12, Bloomberg Earnings reports. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. The firm had revenue of $48.16 million during the quarter, compared to analysts’ expectations of $48.12 million. During the same quarter last year, the business earned $1.09 earnings per share. The business’s revenue for the quarter was up 25.0% compared to the same quarter last year.

Several analysts recently commented on ANIP shares. Canaccord Genuity started coverage on shares of ANI Pharmaceuticals in a research note on Monday, July 31st. They issued a “buy” rating and a $60.00 price objective for the company. BidaskClub upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. ANI Pharmaceuticals has an average rating of “Hold” and an average price target of $67.33.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Earnings History for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.